Skip to main content

Fibrodysplasia Ossificans Progressiva (FOP)

1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Incyte
IncyteDE - Wilmington
1 program
1
INCB000928Phase 21 trial
Active Trials
NCT05090891Recruiting98Est. Jan 2033
Regeneron
RegeneronTARRYTOWN, NY
1 program
Non-InterventionalN/A1 trial
Active Trials
NCT06064656Completed131Est. Sep 2023
Ipsen
IpsenChina - Tianjin
1 program
PalovarotenePHASE_31 trial
Active Trials
NCT05027802Completed61Est. Nov 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
IpsenPalovarotene
IncyteINCB000928
RegeneronNon-Interventional

Clinical Trials (3)

Total enrollment: 290 patients across 3 trials

NCT05027802IpsenPalovarotene

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

Start: Mar 2022Est. completion: Nov 202461 patients
Phase 3Completed
NCT05090891IncyteINCB000928

To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva

Start: May 2022Est. completion: Jan 203398 patients
Phase 2Recruiting
NCT06064656RegeneronNon-Interventional

A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Start: Jun 2023Est. completion: Sep 2023131 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 290 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.